Action required: Please refresh your browser
We have recently implemented some changes that require a hard refresh of your browser: Please hold down the CTRL-key and press the F5 key.
After a successful hard refresh, this message should not appear anymore.
More details about this topic are available here »
| Hemato Oncology Testing Market worth $5.6 billion by 2027 - Exclusive Report by MarketsandMarkets™ | ||
| By: PR Newswire Association LLC. - 23 Nov 2022 | Back to overview list |
|
|
CHICAGO, Nov. 23, 2022 /PRNewswire/ -- Hemato Oncology Testing Market is projected to reach USD 5.6 billion by 2027 from an estimated USD 2.9 Billion in 2022, at a CAGR of 14.2% according to a new report by MarketsandMarkets™. The growth in this market is attributed to the growing incidence of hematologic cancer, increasing collaborations, and the increasing number of conferences on personalized medicine.
Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=262472877 Browse in-depth TOC on "Hemato Oncology Testing Market" The Services segment accounted for the largest share of the Hemato oncology testing devices market, by product type, in 2021 On the basis of products & services type, the global hemato oncology testing market is segmented into services and assay kits. The services segment accounted for the largest share of the global hemato oncology testing market in 2021. This can be attributed to the high and growing prevalence of leukemia and lymphoma. The segment accounted for the largest share of the Hemato oncology testing devices market, by cancer type, in 2021 By cancer type, the global leukemia, lymphoma, and other cancers market. In 2021, the lymphoma segment dominated the global market. This can be attributed to factor such as the increasing prevalence and incidence of lymphoma is a major driving factor for this market. PCR segment is anticipated to hold major share of the global Hemato oncology testing market in 2021 By technology, the global hemato oncology testing market is broadly segmented into PCR, IHC, NGS, cytogenetics, and other technologies. In 2021, the PCR segment dominated hemato oncology testing market. Factors supporting the growth of the segment is the wide use of this technology owing to its ease of use and easy availability of assay kits. Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=262472877 North America to hold a significant share of the Hemato oncology testing market during the forecast period in 2021 The global hemato oncology testing market is segmented into North America, Europe, Asia Pacific, and ROW. North America dominated hemato oncology testing market. The largest share can be attributed to the significant advances have been made in cancer treatment driven by advances in personalized medicine, increasing co-development projects, and increasing collaborations for developing new assay tests. The major players operating in the Hemato oncology testing market Abbott Laboratories (US), F. Hoffman-La Roche (Switzerland), QIAGEN (Germany), Thermo Fisher Scientific (US), Illumina (US), Bio-Rad Laboratories (US), MolecularMD (Ireland), ArcherDX (US), ARUP Laboratories (US), Asuragen (US), Invivoscribe (US), Adaptive Biotechnologies (US), Amoy Diagnostics (China), ELITechGroup (France), Vela Diagnostics (Singapore), Gentronix (UK), BioIVT (US), SAGA Diagnostics (Sweden), Olink (Sweden) and Cancer Diagnostics (US). Get 10% Free Customization on this Report: https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=262472877 Browse Adjacent Market: Medical Devices Market Research Reports & Consulting Related Reports: Molecular Diagnostics Market - Global Forecasts to 2027 Infectious Disease Diagnostics Market - Global Forecasts to 2027 In vitro Diagnostics Market - Global Forecasts to 2026 Companion Diagnostics Market - Global Forecasts to 2026 Point of Care Molecular Diagnostics Market - Global Forecasts to 2026 About MarketsandMarkets™: MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. We have the widest lens on emerging technologies, making us proficient in co-creating supernormal growth for clients. The B2B economy is witnessing the emergence of $25 trillion of new revenue streams that are substituting existing revenue streams in this decade alone. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines - TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing. Built on the 'Give Growth' principle, we work with several Forbes Global 2000 B2B companies - helping them stay relevant in a disruptive ecosystem. Our insights and strategies are molded by our industry experts, cutting-edge AI-powered Market Intelligence Cloud, and years of research. The KnowledgeStore™ (our Market Intelligence Cloud) integrates our research, facilitates an analysis of interconnections through a set of applications, helping clients look at the entire ecosystem and understand the revenue shifts happening in their industry. To find out more, visit www.MarketsandMarkets™.com or follow us on Twitter, LinkedIn and Facebook. Contact: Logo: https://mma.prnewswire.com/media/660509/MarketsandMarkets_Logo.jpg
SOURCE MarketsandMarkets 
|
||
|
|
||
 | Back to overview list | |
View original content to download multimedia: